[lungindia]: Acknowledgment of Online Submission: lungindia_182_19

2 pesan

Lung India <editor@lungindia.com> 24 April 2019 06,17
Balas Ke: laksmi.wulandari@fk.unair.ac.id
Kepada: laksmi.wulandari@fk.unair.ac.id

If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,

NOTE: This e-mail is sent to you as one of the contributing authors. If you are not corresponding author, please coordinate with the author designated by your group as the corresponding author for this manuscript.

A manuscript has been submitted to our journal Lung India by Laksmi Wulandari titled "T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSED ON FIRST-LINE TYROSINE KINASE INHIBITORS THERAPY IDENTIFIED BY CIRCULATING TUMOR DNA TEST: A copy of the acknowledgment mail is attached here with for your reference.

Thanking you
Editorial Team
Lung India

Dear Dr. Wulandari,

Lung India has received your manuscript entitled "T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSED ON FIRST-LINE TYROSINE KINASE INHIBITORS THERAPY IDENTIFIED BY CIRCULATING TUMOR DNA TEST" for consideration for publication. The reference number for this manuscript is "lungindia_182_19". Kindly quote this in correspondence related to this manuscript.

The manuscript is being reviewed for possible publication with the understanding that it is being submitted to one journal at a time and have not been published, simultaneously submitted, or already accepted for publication elsewhere either as a whole or in part. Online submission of this article implies that the corresponding author has the written consent from all the contributors to act as corresponding author.

You are requested to send the signed copyright/contributor form within two weeks. The form can be uploaded as an scanned image from your area. The decision about the manuscript will be conveyed only on receipt of the form. High resolution images are required at the time of acceptance, you should be notified separately for the same, if images uploaded by you are not of printable quality.

The Editors will review the submitted manuscript initially. If found suitable, it will follow a double-blinded peer review. We aim to finish this review process within a short time frame, at the end of which a decision on the suitability or otherwise of the manuscript will be conveyed to you via this system. During this process you are free to check the progress of the manuscript through various phases from our online manuscript processing site http://www.journalonweb.com/lungindia.

We thank you for submitting your valuable work to the Lung India.

Yours sincerely,
The Editorial Team
Lung India

Message sent on Tuesday, April 23, 2019
Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

---- END OF MESSAGE ----
Kepada: laksni.wulandari@fk.unair.ac.id

If you cannot see this page properly, please click here.

Dear Dr. Wulandari,

Lung India has received your manuscript entitled "T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESS ON FIRST-LINE TYROSINE KINASE INHIBITORS THERAPY IDENTIFIED BY CIRCULATING TUMOR DNA TEST" for consideration for publication. The reference number for this manuscript is "lungindia_182_19". Kindly quote this in correspondence related to this manuscript.

The manuscript is being reviewed for possible publication with the understanding that it is being submitted to one journal at a time and have not been published, simultaneously submitted, or already accepted for publication elsewhere either as a whole or in part. Online submission of this article implies that the corresponding author has the written consent from all the contributors to act as corresponding author.

You are requested to send the signed copyright/contributor form within two weeks. The form can be uploaded as an scanned image from your area. The decision about the manuscript will be conveyed only on receipt of the form. High resolution images are required at the time of acceptance, you should be notified separately for the same, if images uploaded by you are not of printable quality.

The Editors will review the submitted manuscript initially. If found suitable, it will follow a double-blinded peer review. We aim to finish this review process within a short time frame, at the end of which a decision on the suitability or otherwise of the manuscript will be conveyed to you via this system. During this process you are free to check the progress of the manuscript through various phases from our online manuscript processing site http://www.journalonweb.com/lungindia.

We thank you for submitting your valuable work to the Lung India.

Yours sincerely,
The Editorial Team
Lung India

Message sent on Tuesday, April 23, 2019
Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

[Kutipan teks disembunyikan]
[lungindia]:Article provisionally accepted.:lungindia_182_19
2 pesan

Lung India <editor@lungindia.com> 12 Oktober 2019 11,12
Kepada: laksmi.wulandari@fk.unair.ac.id

If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,

NOTE: This e-mail is sent to you as one of the contributing authors. If you are not corresponding author, please co-
ordinate with the author designated by your group as the corresponding author for this manuscript

Status of the manuscript titled 'T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO
PROGRESSED ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST' submitted by Mrs. Laksmi
Wulandari has been changed and a copy of the mail is as;

Dear Mrs. Wulandari,

We are pleased to inform that your manuscript "T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS
WHO PROGRESSED ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST" is provisionally
accepted. You would receive an edited version of article in about 3-4 weeks from the date assigned for a final check
and correction. Please overlook the phase exit date.

We thank you for submitting your valuable research work to Lung India.
With warm personal regards,

Yours sincerely,
Virendra Singh
Lung India

Remarks:

Message sent on Saturday, October 12, 2019
Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

---- END OF MESSAGE ----

Lung India <editor@lungindia.com> 12 Oktober 2019 11,12
Kepada: laksmi.wulandari@fk.unair.ac.id

If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,

We are pleased to inform that your manuscript "T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS
WHO PROGRESSED ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST" is provisionally
accepted. You would receive an edited version of article in about 3-4 weeks from the date assigned for a final check
and correction. Please overlook the phase exit date.

We thank you for submitting your valuable research work to Lung India.
With warm personal regards,

Yours sincerely,
Virendra Singh
Lung India

Remarks:

[Kutipan teks disembunyikan]
If you cannot see this page properly, please [click here.](https://mail.google.com/mail/u/2?ik=2047ebe53c&view=pt&search=all&permthid=thread-f%3A1648152729903253934&simpl=msg-f%3A1648152...)

Dear Mrs. Wulandari,

The Editorial Board of Lung India is pleased to inform you that your manuscript entitled T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSED ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST, with manuscript number lungindia_182_19, is acceptable for publication in the Journal. We will be sending you the page proofs through the manuscript management site before publication of the manuscript. At that time, you may place the order for the extra reprints.

If you have not sent the copyright form signed by all the contributors and the images, if any, till now, you are requested to do so at the earliest. Copyright form can be emailed to copyright@medknow.com Copyright form can be emailed to copyright@medknow.com

Please note that the journal reserves the rights to make changes in the language, grammar, presentation, etc. to suit the journal's requirements.

We thank you for submitting your valuable research work to Lung India.

With warm personal regards,
Yours sincerely,
The Editorial Team
Lung India

--- END OF MESSAGE ---
If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,
An edited and formatted version of your article 'T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSED ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST', which is scheduled for publication in a forthcoming issue of Lung India, has been uploaded on our site http://www.journalonweb.com/lungindia.
You are requested to check the same and upload corrected file within 5 days, if there are no changes click "No change" on the site.
If you have any difficulty in downloading or uploading the proofs, please write to proofs@medknow.com.
In case we do not hear from you within the stipulated time, we may proceed with publication of the article as it is or postpone the publication to the next issue.
We value your support to our journal and look forward for your valuable contribution in future.
Thanking you,
Editor
Lung India

Message sent on Friday, October 25, 2019
Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

---- END OF MESSAGE ----
Lung India <editor@lungindia.com>
Kepada: laksmi.wulandari@fk.unair.ac.id

31 Oktober 2019 12,38

If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,

An edited and formatted version of your article 'T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSION ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST', which is scheduled for publication in a forthcoming issue of Lung India, has been uploaded on our site http://www.journalonweb.com/lungindia.

You are requested to check the same and upload corrected file within 5 days. if there are no changes click "No change" on the site.

If you have any difficulty in downloading or uploading the proofs, please write to proofs@medknow.com.

In case we do not hear from you within the stipulated time, we may proceed with publication of the article as it is or postpone the publication to the next issue.

We value your support to our journal and look forward for your valuable contribution in future.

Thanking you,

Editor
Lung India

Message sent on Thursday, October 31, 2019

Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

---- END OF MESSAGE ----
If you cannot see this page properly, please click here.

Dear Mrs. Wulandari,
An edited and formatted version of your article 'T790M MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WHO PROGRESSION ON FIRST-LINE EGFR-TKI THERAPY IDENTIFIED BY ctDNA TEST', which is scheduled for publication in a forthcoming issue of Lung India, has been uploaded on our site http://www.journalonweb.com/lungindia.
You are requested to check the same and upload corrected file within 5 days. If there are no changes click "No change" on the site.
If you have any difficulty in downloading or uploading the proofs, please write to proofs@medknow.com.
In case we do not hear from you within the stipulated time, we may proceed with publication of the article as it is or postpone the publication to the next issue.
We value your support to our journal and look forward for your valuable contribution in future.
Thanking you,
Editor
Lung India

Message sent on Monday, November 4, 2019
Please add editor@lungindia.com as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

---- END OF MESSAGE ----
Dear Dr. Wulandari,

We are pleased to inform that your article entitled “T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors” has been published in “Lung India”. With this mail we are sending you the final PDF of the article for your personal use.

The internet today provides more opportunities than before to improve the visibility of your research work. There have been some studies to show direct correlation of article downloads to citations received. The journal's website and its bibliographic linking does help you to get readers, however, additional linking by you would help you to get even higher citations and research impact. You can use few (or all) of the online tools for this purpose.

1. If your institution has an open archive repository, you can put the PDF of your article in the archive with a link to the article on the journal’s website http://www.lungindia.com/text.asp?2020/37/13/274414. Check http://www.eprints.org/openaccess/self-faq/#self-archiving to learn more about archiving.


3. Link your paper from as many websites as possible using citation and social book marking tools such as GetCited, CiteULike, Connota, Zotero, etc. The URLs for registering with few of these sites are http://www.getcited.org/add/ http://www.citeulike.org/register http://www.connota.org/register http://www.zotero.org/ http://www.stumbleupon.com/sign_up.php?pre2=hp_join

4. Link the article from an appropriate topic in the Wikipedia e.g. http://en.wikipedia.org/wiki/Acanthamoeba_keratitis#References [Ref. 5] or http://en.wikipedia.org/wiki/Hallermann-Streiff_syndrome#References [Ref 4]

5. As an author you can also deposit your paper with the NLM’s PubMedCentral, if you have received an NIH grant. Use the myNCBI link on http://www.nihms.nih.gov/db/sub.cgi to submit your paper.


Thank you for your contribution to our journal.

With personal regards

Lung India

---

LungIndia_2020_37_1_13_274414.pdf

2451K